Substance / Medication

Bexarotene

Overview

Active Ingredient
bexarotene
RxNorm CUI
233272

Indications

Bexarotene capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.

Labeler: AvKAREUpdated: 2025-10-13T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

(8.1) Bexarotene is a member of the retinoid class of drugs that is associated with birth defects in humans. Bexarotene also caused birth defects when administered orally to pregnant rats. Bexarotene must not be administered to a pregnant woman.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: A systematic review and meta-analysis.
Ginsburg Erica, Hennessy Kerry, Mhaskar Rahul et al. · Dermatol Ther · 2022
PMID: 35243730Meta-Analysis
Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
Cummings Jeffrey L, Zhong Kate, Kinney Jefferson W et al. · Alzheimers Res Ther · 2016
PMID: 26822146RCTFull text (PMC)
Comparative evaluation of the biological characteristics of a novel retinoid X receptor agonist and bexarotene.
Tomita Koji, Nakashima Ken-Ichi, Yamaguchi Eiji et al. · Mol Pharmacol · 2025
PMID: 40701035Observational
Bexarotene-induced hypothyroidism and dyslipidemia; a nation-wide study.
Manaka Katsunori, Sato Junichiro, Hikima Yusuke et al. · Endocr J · 2024
PMID: 38839346Observational
Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R, Gainza-Apraiz I, Ortiz-Romero P et al. · Actas Dermosifiliogr · 2024
PMID: 38395224Observational
Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma.
Elsayad Khaled, Rolf Daniel, Sunderkötter Cord et al. · J Dtsch Dermatol Ges · 2022
PMID: 34984837Observational
Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients.
Toi Norikazu, Kurajoh Masafumi, Miyaoka Daichi et al. · Endocr J · 2022
PMID: 34433736Observational
Novel bexarotene derivatives: Synthesis and cytotoxicity evaluation for glioma cells in 2D and 3D in vitro models.
Gretskaya Natalia M, Gamisonia Alina M, Dudina Polina V et al. · Eur J Pharmacol · 2020
PMID: 32659303Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bexarotene (substance)
SNOMED CT
387023000
UMLS CUI
C0765273
RxNorm CUI
233272
Labeler
AvKARE

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.